Sagimet Biosciences Inc. (SGMT)
4.33
0.17 (4.21%)
At close: Jan 15, 2025, 11:15 AM
undefined% (undefined)
| Bid | 4.31 |
| Market Cap | 132.82M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.39 |
| PE Ratio (ttm) | -11.1 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.32 |
| Volume | 616,821 |
| Avg. Volume (20D) | 912,649 |
| Open | 4.31 |
| Previous Close | 4.16 |
| Day's Range | 4.12 - 4.52 |
| 52-Week Range | 2.39 - 20.71 |
| Beta | undefined |
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 17, 2023
Employees 8
Stock Exchange NASDAQ
Ticker Symbol SGMT
Website https://sagimet.com
Analyst Forecast
According to 6 analyst ratings, the average rating for SGMT stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 546.65% from the latest price.
Buy 83.33%
Hold 16.67%
Sell 0.00%
2 months ago ·
Source
-13.95%
Sagimet Biosciences shares are trading lower after...
Unlock content with
Pro Subscription
3 months ago ·
Source
+20.42%
Sagimet Biosciences shares are trading higher. The company on Friday announced that results from the Phase 2b FASCINATE-2 clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic-dysfunction associated steatohepatitis patients with stage 2 or stage 3 fibrosis were published in The Lancet Gastroenterology & Hepatology.
